Estimation of Tacrolimus Clearance in Saudi Adult Kidney Transplant Recipients

被引:6
作者
Alqahtani, Saeed [1 ,2 ]
Alenazi, Maha [3 ]
Alsultan, Abdullah [1 ,2 ]
Alsarhani, Emad [1 ,2 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Clin Pharm, POB 2457, Riyadh 11451, Saudi Arabia
[2] King Saud Univ Med City, Clin Pharmacokinet & Pharmacodynam Unit, Riyadh, Saudi Arabia
[3] Prince Sultan Cardiac Ctr, Dept Pharm, Riyadh, Saudi Arabia
关键词
POPULATION PHARMACOKINETIC PARAMETERS; CLINICAL PHARMACOKINETICS; ACUTE REJECTION; RISK-FACTOR; VARIABILITY; FK506; BIOAVAILABILITY; ETHNICITY; IMPACT; LIVER;
D O I
10.4103/1319-2442.318511
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Tacrolimus is commonly used in adult kidney transplant patients. Only few studies have so far described the pharmacokinetics of tacrolimus in the Saudi population. Thus, the goal of this study is to determine the population pharmacokinetics of tacrolimus in Saudi adult kidney transplant recipients and to identify the factors that explain variability. We performed a retrospective chart review of adult patients who received oral tacrolimus at two centers. We developed the population pharmacokinetic models using Monolix 4.4. The factors screened for influence on these parameters were weight, age, gender, liver function tests, and creatinine clearance. The analysis included a total of 149 tacrolimus plasma concentrations from 139 patients. A one-compartment open model with linear absorption and elimination adequately described the data. The average parameter estimates for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 9.1 L/h and 912 L, respectively. The interindividual variabilities (coefficients of variation) in CL/F and V/F were 20% and 18%, respectively. Aspartate aminotransferase was identified to be the main covariate that influences tacrolimus CL/F. In conclusion, the population pharmacokinetic model of tacrolimus was established and a significant covariate of the model was identified. These findings offer a rationale for the personalization of tacrolimus dosing regimens. Further studies are required to understand the factors that may influence the pharmacokinetics of tacrolimus and assist in drug dosage decisions.
引用
收藏
页码:101 / 110
页数:10
相关论文
共 49 条
[1]  
Abou-Auda HS, 2019, J PHARM THER, V5, P288
[2]   Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients [J].
Andrews, Louise M. ;
Li, Yi ;
De Winter, Brenda C. M. ;
Shi, Yun-Ying ;
Baan, Carla C. ;
Van Gelder, Teun ;
Hesselink, Dennis A. .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (12) :1225-1236
[3]   Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients [J].
Antignac, Marie ;
Barrou, Benoit ;
Farinotti, Robert ;
Lechat, Philippe ;
Urien, Saik .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (06) :750-757
[4]   Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose [J].
Bekersky, I ;
Dressler, D ;
Mekki, Q .
JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (03) :289-297
[5]   Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects [J].
Bekersky, I ;
Dressler, D ;
Mekki, QA .
JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (02) :176-182
[6]   Trough Tacrolimus Concentrations in the First Week After Kidney Transplantation Are Related to Acute Rejection [J].
Borobia, Alberto M. ;
Romero, Ivan ;
Jimenez, Carlos ;
Gil, Fernando ;
Ramirez, Elena ;
De Gracia, Raquel ;
Escuin, Fernando ;
Gonzalez, Elena ;
Carcas Sansuan, Antonio J. .
THERAPEUTIC DRUG MONITORING, 2009, 31 (04) :436-442
[7]   High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation [J].
Borra, Lennaert C. P. ;
Roodnat, Joke I. ;
Kal, Judith A. ;
Mathot, Ron A. A. ;
Weimar, Willem ;
van Gelder, Teun .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (08) :2757-2763
[8]   Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet? [J].
Brooks, Emily ;
Tett, Susan E. ;
Isbel, Nicole M. ;
Staatz, Christine E. .
CLINICAL PHARMACOKINETICS, 2016, 55 (11) :1295-1335
[9]   Immune therapies of autoimmune diseases: are we approaching a real cure? [J].
Chatenoud, Lucienne .
CURRENT OPINION IN IMMUNOLOGY, 2006, 18 (06) :710-717
[10]   The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring [J].
Felipe, CR ;
Silva, HT ;
Machado, PG ;
Garcia, R ;
Moreira, SRD ;
Pestana, JO .
CLINICAL TRANSPLANTATION, 2002, 16 (04) :262-272